Merck's Q2 Sales Surge, Hitting $16.6 Billion
Merck, a leading pharmaceutical company listed on the NYSE under the ticker MRK, has released its financial results for Q2 2026. The company achieved worldwide sales of $16.6 billion during this period.
The strong performance was attributed to continued growth in oncology and animal health segments, as well as increasing contributions from new product launches. Rob Davis, Chairman and CEO of Merck, stated that the company has made 'substantial progress' across its business, driven by strong execution and growing contributions from new product launches.
One notable achievement mentioned was the FDA approval of LIPFENDRA, which is seen as a significant moment for the company and patients. The approval reflects the strength of Merck's pipeline and portfolio transformation as it brings forward innovation. Davis expressed confidence in the ongoing execution of the company's strategy, aiming to deliver for patients and enhance its long-term growth trajectory.
Looking ahead, Merck anticipates full-year 2026 worldwide sales to range between $66.3 billion and $67.3 billion.